Clearside Biomedical Inc (NASDAQ:CLSD) Director Clay Thorp sold 15,941 shares of the company’s stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $8.94, for a total value of $142,512.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Clay Thorp also recently made the following trade(s):

  • On Tuesday, May 16th, Clay Thorp sold 9,544 shares of Clearside Biomedical stock. The stock was sold at an average price of $8.61, for a total value of $82,173.84.
  • On Wednesday, May 17th, Clay Thorp sold 44,485 shares of Clearside Biomedical stock. The stock was sold at an average price of $8.63, for a total value of $383,905.55.
  • On Tuesday, April 18th, Clay Thorp sold 44,455 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.48, for a total value of $332,523.40.
  • On Monday, April 17th, Clay Thorp sold 22,000 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.43, for a total value of $163,460.00.
  • On Wednesday, April 19th, Clay Thorp sold 68,485 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.46, for a total value of $510,898.10.
  • On Thursday, March 16th, Clay Thorp sold 68,485 shares of Clearside Biomedical stock. The stock was sold at an average price of $6.56, for a total value of $449,261.60.
  • On Wednesday, February 22nd, Clay Thorp sold 27,000 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.55, for a total value of $203,850.00.
  • On Friday, February 17th, Clay Thorp sold 41,485 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.60, for a total value of $315,286.00.

Clearside Biomedical Inc (NASDAQ:CLSD) traded down 3.66% during midday trading on Friday, hitting $8.16. The company had a trading volume of 81,926 shares. The firm’s market capitalization is $206.45 million. Clearside Biomedical Inc has a 1-year low of $5.44 and a 1-year high of $25.08. The company has a 50 day moving average price of $7.94 and a 200 day moving average price of $10.13.

Clearside Biomedical (NASDAQ:CLSD) last posted its quarterly earnings data on Wednesday, May 10th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.44) by $0.03. The firm had revenue of $0.01 million during the quarter. Equities research analysts forecast that Clearside Biomedical Inc will post ($1.73) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Clearside Biomedical (NASDAQ:CLSD)

ILLEGAL ACTIVITY NOTICE: “Clay Thorp Sells 15,941 Shares of Clearside Biomedical Inc (CLSD) Stock” was first posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.watchlistnews.com/clay-thorp-sells-15941-shares-of-clearside-biomedical-inc-clsd-stock/1290419.html.

A number of large investors have recently bought and sold shares of CLSD. Hillhouse Capital Management Ltd. purchased a new stake in Clearside Biomedical during the third quarter valued at about $10,410,000. State Street Corp boosted its stake in Clearside Biomedical by 80.7% in the fourth quarter. State Street Corp now owns 102,278 shares of the company’s stock valued at $911,000 after buying an additional 45,671 shares during the last quarter. FMR LLC boosted its stake in Clearside Biomedical by 377.3% in the fourth quarter. FMR LLC now owns 1,029,600 shares of the company’s stock valued at $9,205,000 after buying an additional 813,889 shares during the last quarter. Marshall Wace LLP boosted its stake in Clearside Biomedical by 181.1% in the fourth quarter. Marshall Wace LLP now owns 449,820 shares of the company’s stock valued at $4,021,000 after buying an additional 289,820 shares during the last quarter. Finally, Acuta Capital Partners LLC purchased a new stake in Clearside Biomedical during the fourth quarter valued at about $1,565,000. Institutional investors own 33.52% of the company’s stock.

A number of equities analysts have recently weighed in on the company. Zacks Investment Research raised Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Monday, April 3rd. Wedbush reiterated an “outperform” rating and issued a $27.00 target price on shares of Clearside Biomedical in a research report on Thursday, April 20th. Cowen and Company reiterated a “buy” rating and issued a $15.00 target price on shares of Clearside Biomedical in a research report on Thursday, May 11th. Needham & Company LLC decreased their target price on Clearside Biomedical to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, March 14th. Finally, JPMorgan Chase & Co. initiated coverage on Clearside Biomedical in a research report on Friday, February 24th. They issued an “overweight” rating and a $19.00 target price on the stock. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $20.67.

About Clearside Biomedical

Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.

5 Day Chart for NASDAQ:CLSD

Receive News & Ratings for Clearside Biomedical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.